{"name":"Coherus Oncology, Inc.","slug":"coherus-oncology-inc","ticker":"","exchange":"","domain":"coherusoncology.com","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"Pharma / Biotech","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Oncology","slug":"oncology","revenue":0,"percentOfTotal":0,"drugCount":2,"colorKey":"oncology","drugs":[{"name":"CHS-0214","genericName":"CHS-0214","slug":"chs-0214","indication":"Solid tumors (specific indication under clinical development)","status":"phase_3"},{"name":"CHS-1420","genericName":"CHS-1420","slug":"chs-1420","indication":"Advanced or metastatic solid tumors (Phase 3 development)","status":"phase_3"}]},{"name":"Hematology","slug":"hematology","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"immunology","drugs":[{"name":"Pegfilgrastim-Cbqv","genericName":"Pegfilgrastim-Cbqv","slug":"pegfilgrastim-cbqv","indication":"Chemotherapy-induced neutropenia (CIN) in patients with non-myeloid malignancies receiving myelosuppressive chemotherapy","status":"marketed"}]}],"pipeline":[{"name":"CHS-0214","genericName":"CHS-0214","slug":"chs-0214","phase":"phase_3","mechanism":"CHS-0214 is a bispecific antibody that simultaneously engages CD3 on T cells and a tumor-associated antigen to redirect immune cells to kill cancer cells.","indications":["Solid tumors (specific indication under clinical development)"],"catalyst":""},{"name":"CHS-1420","genericName":"CHS-1420","slug":"chs-1420","phase":"phase_3","mechanism":"CHS-1420 is a bispecific antibody that simultaneously engages CD47 on tumor cells and CD40 on antigen-presenting cells to enhance anti-tumor immunity.","indications":["Advanced or metastatic solid tumors (Phase 3 development)"],"catalyst":""},{"name":"Pegfilgrastim-Cbqv","genericName":"Pegfilgrastim-Cbqv","slug":"pegfilgrastim-cbqv","phase":"marketed","mechanism":"Pegfilgrastim-Cbqv is a pegylated granulocyte colony-stimulating factor (G-CSF) analog that stimulates the proliferation and differentiation of neutrophil progenitor cells to increase circulating neutrophil counts.","indications":["Chemotherapy-induced neutropenia (CIN) in patients with non-myeloid malignancies receiving myelosuppressive chemotherapy","Reduction of duration of severe neutropenia in patients with non-myeloid malignancies receiving myeloablative chemotherapy followed by hematopoietic stem cell transplantation"],"catalyst":""}],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMilwFBVV95cUxPVnd6SXppc3ktY182b0pVMDBmMmF2WU1ZRXZSNXNRU1FDWHRnN0FkUWZnYkpsanctbUY4b1dDWEdzdVpkcGtjSWNVcU1xdm9xNWlJOTBILTdwSjlUNWJpckktdEVqSVg2dlMxVUljdjZ0YTdaTnlHSWNCSzlLQkFGWjQwWndrZDZFYW9oWFBObFdfUUpYczJN?oc=5","date":"2026-02-17","type":"pipeline","source":"Pharma Voice","summary":"More drugmakers are turning to cancer combos. Will it help patients live longer? - Pharma Voice","headline":"More drugmakers are turning to cancer combos. Will it help patients live longer?","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMitAFBVV95cUxOdy1IR0tvZ25HUGowMjByem5DQzdpYWt4WWpIUEZwMGNueG5LSmtBNXJMWFFkN0pfV3VuSnBlX0UxOVZWdllZLXRQb1VjbVg3eXpLd0ZrMUlySzc3NFhQYmRzQ2xLS1hCMmNPSGU4SWpYUHF3MV9icDI4RnNKeEludUZJMWdHYnVPMVZBZWp1T2l3NkZZakRPTjVnWmlZbk83bm13N3RjdXhxbk9oVFpVdWhubzQ?oc=5","date":"2026-02-13","type":"pipeline","source":"Benzinga","summary":"12 Health Care Stocks Moving In Friday's Pre-Market Session - Benzinga","headline":"12 Health Care Stocks Moving In Friday's Pre-Market Session","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiwgFBVV95cUxPbHdKaFJRSWo3WmNOeFExaUpJQUxLVGxoMW5yQ3FHY3NyaFd6VzhuejMzRW12WElqdGhyeWZXbUF6dHptQVk2cFVNMVhHZGdzZnBhMHd3TDNNUTZpWDVkMnBsUEplRzc2X0hsUmlhZGtpYXJ3d1JPbm5hQ2hNUGdqVHpxbkVfTGFEZGNHQUh5Qkd6ejBGYWhrM1paM253VUV3M2NHVl9OcHVvTXYwNWxUcVBxd3lUeHRQY3kxX3pEZDVvZw?oc=5","date":"2026-02-13","type":"pipeline","source":"Investing.com","summary":"Coherus Oncology prices $50.1 million public offering of common stock - Investing.com","headline":"Coherus Oncology prices $50.1 million public offering of common stock","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMikAFBVV95cUxQWFhOWS1VOGxxSWFNclR6MUo1QUI4T3g1LWZqWFIwNl9abnB3dlRXUnQtQ0pzWnJsZ256X0tvMkZuLURsQ0M2OFI0VW81MmRCOEctV042eUU1UUE4VzhrUHFmbzlIeUZzcUZuX3hYUktXZVRJb1pHQnFaaEhobURQaFFFS3NiQ2ZIZXNxVFNNQzA?oc=5","date":"2026-02-05","type":"deal","source":"The Pharma Letter","summary":"Coherus Oncology announces deal with J&J - The Pharma Letter","headline":"Coherus Oncology announces deal with J&J","sentiment":"neutral"},{"url":"https://news.google.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?oc=5","date":"2026-01-26","type":"pipeline","source":"simplywall.st","summary":"Coherus Oncology (CHRS) Taps ATM Facility: Strategic Lifeline or Dilution Trade-Off for Its Pipeline? - simplywall.st","headline":"Coherus Oncology (CHRS) Taps ATM Facility: Strategic Lifeline or Dilution Trade-Off for Its Pipeline?","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMigAFBVV95cUxQelBlREZKcDF4YVg5TVRhZ19PRWlKdGlVOE1ORkQ5NEx1M1Y4M1lfV2NHNDlnN0JlZGRYdnZtUmJKUDFNaFNpSWM5Q0R1cndEN3dMWjJLSmJLMjFzVFhaNGEzSkNudlNlT1Z1N1o0OUVmY3AzU0NpS3dXaWx0SDlHLQ?oc=5","date":"2026-01-14","type":"pipeline","source":"Yahoo Finance","summary":"Ascendis Pharma (ASND) Surges 3.0%: Is This an Indication of Further Gains? - Yahoo Finance","headline":"Ascendis Pharma (ASND) Surges 3.0%: Is This an Indication of Further Gains?","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMirgFBVV95cUxPN1ZnQW1TNTA1ZHVmcmJCQjY5aVJ5STRhVDFiUS1jZXRkQ05tNERudHhGazAtNU44RFROV1Y1M3ZVXzRZQXY4MlVzU25tQzNqbU1sZ1A1MHp2RXpvcTViNzdCb2g5WWJJUVdsM0NoWG5pUDV1cHctU1F0VG5YMkQ2aGxpNDBjRUNQUzAxLXpHWGdMVmJmTmwtQlRtRTNIVkRvbFN4RlBXUkUzSHRfWEE?oc=5","date":"2025-06-05","type":"pipeline","source":"Fierce Pharma","summary":"Fujifilm, Coherus, ViGeneron unveil rebrands to better reflect ongoing work - Fierce Pharma","headline":"Fujifilm, Coherus, ViGeneron unveil rebrands to better reflect ongoing work","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMingFBVV95cUxOVlBkdmVaRmtEeWhyM2ZhdWFQVlhjb2RfOTlMZGlURGlTZmZtbTE1RDRJZW5CdlZIdDdBWlVuZl9BRFZVZWdBUENfZ2RrMlB1VzAxNzBndWowLWVVbl9vS3Z3S3FHZFhuazYtSWY5dEVWQUNNOGNGYUNpSS1TSUd0czhhMUIyVGt2M1BuYmhKWXZJQWxXTFg2THBCenM4UQ?oc=5","date":"2025-04-23","type":"patent","source":"Fierce Pharma","summary":"Coherus loses commercial chief amid exit from biosimilar space - Fierce Pharma","headline":"Coherus loses commercial chief amid exit from biosimilar space","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMisgFBVV95cUxOaDZvZFV1YXNwbkJUa0RCQ3lpVGJiM2F2dDdqZ3pVVzl0NHJTVjZ5YktoXzRqVXhHNmZfZ1dGc3doNzJRS0VCanJLOTg4QTNuZjRBd1RTQlVWN012V1VTTEpiWklTU2dkYlZpcFhCSWluOG1FZ2pmRWdVU05UaEdfNE1TbDJ3VHlLTHU3Q1FIaERYc0RHd3ZLODEteVBkbmFMXzRHd0ZzNHFXaGhCYjUxcFBn?oc=5","date":"2025-04-17","type":"pipeline","source":"Seeking Alpha","summary":"Coherus: Cleaning The Balance Sheet And Developing New Drugs (NASDAQ:CHRS) - Seeking Alpha","headline":"Coherus: Cleaning The Balance Sheet And Developing New Drugs (NASDAQ:CHRS)","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMitwJBVV95cUxOMFNfRXVpYnpkdzFiWE9vTHZOVUZWZk9mSUpsY0F3M18yenlEYi1SUHpYaTV5OFFaRzFQaElVaU55MTA1U2ZkQzBFY0w4VHpfMHo5YlRzdTlRWEQ4OHk3RFdzeE53RUw1d285bU5XWEFwMnBMcjBWTTVBbnVrTVdGY00ybWE0SDJTNG50TG5kYkpzcDJQaG9ocVlQak1mV3JJczg2S2lVTG5vWC1RazdmTzYyRnRyS1g4VlMtcnpXUnA2SzctMUs3V3VVQTd1Um1ScFZJZ0drYUF6MEQtRm9pY0FZV3JlU003d2N3ZkxkOWM0QUlDUS0xRmQtTllDb2xkWlBlSnE3NUtyMHNVUTRyNHhDV3d5blBnOTB4SVczNU9LNHBNUTZ1a1p4ZTg1Tk13NHBNZW1qNA?oc=5","date":"2025-04-14","type":"patent","source":"prnewswire.com","summary":"Accord BioPharma, Inc. Announces Completion of UDENYCA® (pegfilgrastim-cbqv) Franchise Acquisition from Coherus BioSciences, Inc., Expanding U.S. Biosimilar Portfolio - prnewswire.com","headline":"Accord BioPharma, Inc. Announces Completion of UDENYCA® (pegfilgrastim-cbqv) Franchise Acquisition from Coherus BioScien","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMirwFBVV95cUxPejlEZFRzeXo3NjFLT3V2QzV6WEdDRXBDY2o5UjdWMTd2dmQtWWdqR0NJZW1FbE95cEhha19aTjNuQWltU3piRDlrcXBlaHIwQVRxR2tmMVp4NnVTQ09PNW9NSnR4dmdyOTVtdUJtd3ZLbG1zcThvZFRDUWFYb0swbFpGa0N1aExaSVF5VjAtR2VGQUhSTmtRV01YTXZVTVRaMDVvYmpVTndud0lsLWVN?oc=5","date":"2024-12-03","type":"patent","source":"BioPharma Dive","summary":"Coherus, sharpening immuno-oncology focus, sells another biosimilar for over $500M - BioPharma Dive","headline":"Coherus, sharpening immuno-oncology focus, sells another biosimilar for over $500M","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMifEFVX3lxTE5kUy1BbWhmMlpZTzNMV1EyaG5YZjhJYWhHQ19ZbFJJS1RIVjNXZWtkdUtBR2g0bk1JazZ5UVYySWN3NW1wcXBHZGMzNkRDRzkwRHlGV3ctWFJjNGJtWEJlQjJhRExSOGpIWTdpWUFmNlJYQW1pSGUtMVdHbGo?oc=5","date":"2023-09-11","type":"deal","source":"Pharmaceutical Technology","summary":"Coherus acquires immuno-oncology company Surface - Pharmaceutical Technology","headline":"Coherus acquires immuno-oncology company Surface","sentiment":"neutral"}],"patents":[],"drugCount":3,"phaseCounts":{"phase_3":2,"marketed":1},"enrichmentLevel":0,"visitCount":2,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}